The EPO published European Patent Application EP3727419A1 for a novel combination of spermidine and high protein composition designed to induce autophagy. The patent protects compositions and methods for therapeutic use, classified under IPC A61K 38/01, A61K 38/17, A61K 31/132, and A61P 21/00. The application designates 35 contracting states covering the full EPO membership including all EU member states plus Switzerland, Norway, and other European countries.

Regulated entities in the pharmaceutical and nutritional supplement sectors should review this patent to assess freedom-to-operate implications for any competing spermidine and protein combination products targeting autophagy induction. No compliance actions or deadlines apply to this patent publication. Companies developing similar therapeutic compositions should consider patent mapping and potential licensing negotiations with Nestlé.